Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury.
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The clinical trial is designed to evaluate the efficacy of bicyclol for patients with
antineoplastic drug-induced liver injury and investigate factors effecting the therapeutic
outcome.
Phase:
N/A
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital